Article Text


ILD: from bench to bedside and back again
P86 The assessment of health related quality of life in sarcoidosis with the King's Sarcoidosis Questionnaire (KSQ)
  1. A S Patel1,
  2. R Siegert2,
  3. D Creamer3,
  4. G Larkin4,
  5. B Gray1,
  6. A U Wells5,
  7. I J Higginson1,
  8. S S Birring1
  1. 1Division of Asthma, Allergy and Lung biology, King's College London, London, UK
  2. 2Department of Palliative Care, Policy and Rehabilitation, Cicely Saunders Institute, King's College London, London, UK
  3. 3Department of Dermatology, King's College Hospital, London, UK
  4. 4Department of Ophthalmology, King's College Hospital, London, UK
  5. 5Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK


Introduction The King's Sarcoidosis Questionnaire (KSQ) is a recently developed and validated sarcoidosis specific health related quality of life (HRQOL) tool comprising of 5 modules: general HRQOL (10 items), lung (6 items), medication/side-effects (3 items), skin (4 items), and eye (7 items). We set out to evaluate HRQOL in a large group of patients with wide ranging sarcoidosis and determine the factors that influence it.

Methods 207 patients with sarcoidosis (89% lung, 26% skin, 22% eye, 29% other organ involvement) attending outpatient clinics at King's College and Royal Brompton Hospitals completed the KSQ. KSQ domain scores range from 0 to 100, a higher score representing a better HRQOL. Demographic data, immunosuppressant medication, organ involvement, lung function, Scadding CXR stage, physicians global assessment (PGA) of severity of skin disease and visual acuity (VA) were recorded.

Results Patients had a mean (SEM) age 48 (11) years, 54% were female and 30% were Afro-Caribbean. Patients had a mean (SEM) FEV1 80 (23)% predicted, FVC 94 (19)% predicted and TLCO % predicted 66 (17). HRQOL was impaired in all domains, mean (SEM) scores: general HRQOL 51 (2), lung 61 (2), medication/side-effects 49 (3), skin 54 (4), and eye 50 (4). Patients with 2 or more organ involvement compared to single organ involvement had worse general HRQOL (44 (3) vs 58 (3); p<0.01) and worse medication/side-effects scores (44 (3) vs 58 (3); p=0.04). Female patients compared to males had worse general HRQOL (45 (3) vs 57 (3); p<0.01) and medication/side-effects scores (41 (3) vs 58 (4); p<0.01). There were no associations between HRQOL and age (r=−0.02 to 0.13) or ethnicity (p=0.42). There was a weak but significant relationship between lung HRQOL and FEV1 (r=0.38, p<0.01), FVC (r=0.38, p<0.01) and TLCO % predicted (r=0.22, p<0.01). Patients with Scadding CXR stage 3–4 disease compared to stage 0–2 disease had significantly worse lung HRQOL (51 (4) vs 63 (3); p=0.02). Skin health was associated with physician's global assessment (PGA) of severity of skin disease (r=0.51, p<0.01). Eye health was associated with VA (r=−0.56, p<0.01). Patients taking immunosuppressant medication for sarcoidosis compared to those not taking immunosuppresants had significantly worse general HRQOL (45 (2) vs 66 (4); p<0.01) and lung HRQOL scores (58 (3) vs 70 (4); p=0.01).

Conclusions HRQOL is impaired in sarcoidosis. Gender, immunosuppressant medication, multi-system organ involvement and severity of lung function impact on HRQOL. This study provides further clinical validation of the KSQ.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.